Welcome to the Bioasis Technologies Hub On AGORACOM

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Message: It finally happened this morning!
Reply New Message
Prev Message Back To Forum Threaded View Next Message

chrispi ..."This transaction is transformational for Bioasis, bringing Phase 2 ready assets aligned with our focus in rare disease and orphan drug indications. EGF1-48 comes with a full IND package and clinical experience indicating that it is safe and well tolerated in humans."

With having RGFI-48 Phase 2 ready, how does this work in moving forward seeing that the Bioasis XB3 platform technology does not?

“The transfer of these assets to Bioasis will speed up the development of EGF therapeutics for the treatment of certain rare neurodegenerative disorders,”

So once this is all accomplished, does this mean that Bioasis will have a stand-alone drug and own it outright, passing on agreed-upon milestone payments etc.?  

 

Koo

1 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply